Rakovina Therapeutics Inc (TSE:RKV) has launched an replace.
Rakovina Therapeutics Inc. has efficiently accomplished an oversubscribed non-public placement, elevating $2 million to advance its most cancers remedy analysis based mostly on DNA-damage response applied sciences. The funds might be directed in direction of the corporate’s AI-driven drug candidate analysis, with expectations of preliminary information from in vivo fashions later within the 12 months. This capital increase is meant to assist the event of next-generation DDR drug candidates, aiming to enter human scientific trials in partnership with pharmaceutical firms.
For additional insights into TSE:RKV inventory, try TipRanks’ Inventory Evaluation web page.
